WO2004089978A3 - Use of hcv proteins - Google Patents

Use of hcv proteins Download PDF

Info

Publication number
WO2004089978A3
WO2004089978A3 PCT/IE2004/000054 IE2004000054W WO2004089978A3 WO 2004089978 A3 WO2004089978 A3 WO 2004089978A3 IE 2004000054 W IE2004000054 W IE 2004000054W WO 2004089978 A3 WO2004089978 A3 WO 2004089978A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv proteins
agent
protein
hcv
structured protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2004/000054
Other languages
French (fr)
Other versions
WO2004089978A2 (en
Inventor
Kingston Henry Gordon Mills
Miriam Therese Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority to AU2004228476A priority Critical patent/AU2004228476A1/en
Priority to CA002521931A priority patent/CA2521931A1/en
Priority to EP04726601A priority patent/EP1613647A2/en
Publication of WO2004089978A2 publication Critical patent/WO2004089978A2/en
Publication of WO2004089978A3 publication Critical patent/WO2004089978A3/en
Priority to US11/245,153 priority patent/US20060035335A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A Hepatitis C virus (HCV) protein such as a non-structured protein 4 (NS4) or a non-structured protein 3 (NS3) or a derivative or fragment or variant or peptide thereof or product of cells activated by the agent is useful in the treatment and/or prophylaxis of an inflammatory and/or an immune-mediated disorder. The agent can also be used as a vaccine adjuvant.
PCT/IE2004/000054 2003-04-11 2004-04-08 Use of hcv proteins Ceased WO2004089978A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2004228476A AU2004228476A1 (en) 2003-04-11 2004-04-08 Use of HCV proteins
CA002521931A CA2521931A1 (en) 2003-04-11 2004-04-08 Use of hcv proteins
EP04726601A EP1613647A2 (en) 2003-04-11 2004-04-08 Use of hcv proteins
US11/245,153 US20060035335A1 (en) 2003-04-11 2005-10-07 Use of HCV proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE2003/0279 2003-04-11
IE20030279 2003-04-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/245,153 Continuation US20060035335A1 (en) 2003-04-11 2005-10-07 Use of HCV proteins

Publications (2)

Publication Number Publication Date
WO2004089978A2 WO2004089978A2 (en) 2004-10-21
WO2004089978A3 true WO2004089978A3 (en) 2005-03-31

Family

ID=33156181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2004/000054 Ceased WO2004089978A2 (en) 2003-04-11 2004-04-08 Use of hcv proteins

Country Status (5)

Country Link
US (1) US20060035335A1 (en)
EP (1) EP1613647A2 (en)
AU (1) AU2004228476A1 (en)
CA (1) CA2521931A1 (en)
WO (1) WO2004089978A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US20020119495A1 (en) * 2000-09-13 2002-08-29 Nakano Eileen T. Immunogenic composition of hepatitis C and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3425556A1 (en) * 1984-07-11 1986-01-23 Hörmann KG Amshausen, 4803 Steinhagen PROFILE FOR ROLL, SECTIONAL OR THE LIKE GATES
ATE38077T1 (en) * 1985-02-27 1988-11-15 Hoermann Kg FRAME PROFILE.
DE8601984U1 (en) * 1986-01-27 1987-05-27 Hörmann KG Brockhagen, 4803 Steinhagen Gate leaf link
DE3736210A1 (en) * 1987-10-26 1989-05-11 Hoermann Kg DOOR LEAF ELEMENT
DE29706142U1 (en) * 1997-04-07 1997-08-21 MARANTEC Antriebs- und Steuerungstechnik GmbH & Co. Produktions-KG, 33428 Marienfeld Gear for gate drives
US6495229B1 (en) * 1999-09-17 2002-12-17 Avery Dennison Corporation Pattern coated adhesive article

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US20020119495A1 (en) * 2000-09-13 2002-08-29 Nakano Eileen T. Immunogenic composition of hepatitis C and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MACDONALD ANGUS J ET AL: "CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons", JOURNAL OF INFECTIOUS DISEASES, vol. 185, no. 6, 15 March 2002 (2002-03-15), pages 720 - 727, XP009036233, ISSN: 0022-1899 *
WOITAS RAINER P ET AL: "HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C.", WORLD JOURNAL OF GASTROENTEROLOGY : WJG. JUN 2002, vol. 8, no. 3, June 2002 (2002-06-01), pages 562 - 566, XP001183496, ISSN: 1007-9327 *

Also Published As

Publication number Publication date
US20060035335A1 (en) 2006-02-16
WO2004089978A2 (en) 2004-10-21
CA2521931A1 (en) 2004-10-21
AU2004228476A1 (en) 2004-10-21
EP1613647A2 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
EP1303487A4 (en) NOVEL PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
WO2004111082A3 (en) Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
ATE461207T1 (en) PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF THE HEPATITIS C VIRUS
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
ATE212037T1 (en) INHIBITORS OF SERINE PROTEASES, IN PARTICULAR THE NS3 PROTEASE OF THE HEPATITIS C VIRUS
ATE277945T1 (en) MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS NS3 PROTEASE INHIBITORES
AU2002230763A1 (en) Inhibitors of hepatitis c virus ns3 protease
EP1200109A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HEPATITIS C VIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
WO2006090385A3 (en) Protease inhibitors and method of screening thereof
ATE430166T1 (en) DIARYL REST COMPRISING PEPTIDES AS INHIBITORS OF THE NS-3 SERINE PROTEASES OF HEPATITIS C VIRUS
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
ATE195953T1 (en) PEPTIDES FOR INDUCING IMMUNE RESPONSE BY CYTOTOXIC T LYMPHOCYTES AGAINST HEPATITIS C VIRUS
DK0935609T3 (en) Crystallizable preparations comprising a hepatitis C virus NS3 protease domain / NS4A complex and thus obtained crystals
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2009014216A1 (en) Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof
MXPA05005203A (en) Vaccine against hcv.
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
WO2004014936A3 (en) Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof
WO2004089978A3 (en) Use of hcv proteins
WO1999063941A3 (en) Novel hepatitis c virus peptides and uses thereof
WO2002100900A3 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
ATE115964T1 (en) NON-A NON-B SEQUENCES.
WO2004082596A3 (en) Yersinia species compositions
EP1310512A3 (en) Hcv core protein sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521931

Country of ref document: CA

Ref document number: 11245153

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004228476

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 543092

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004726601

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004228476

Country of ref document: AU

Date of ref document: 20040408

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004228476

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004726601

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11245153

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004726601

Country of ref document: EP